Investing in dividend stocks is appealing due to their potential for strong long-term returns, but not all dividend-paying companies are worthwhile. Johnson & Johnson, despite challenges like stagnant revenue growth, ongoing lawsuits, and regulatory pressures affecting drug pricing, remains a solid candidate for income-seeking investors, alongside Merck.
Explain It To Me Like I’m 5: Investing in dividend stocks like Johnson & Johnson and Merck can be smart because they often make money and raise the money they give to you, but Johnson & Johnson has been having some problems lately that might make it less attractive.
Want More Context? 🔎
